Erschienen in:
01.07.2007 | Letter
Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267
verfasst von:
P. D. Home
Erschienen in:
Diabetologia
|
Ausgabe 7/2007
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: In their paper published in
Diabetologia, Nauck and colleagues suggest that exenatide resulted in reductions in HbA
1c and low rates of hypoglycaemia similar to those observed with biphasic insulin aspart (30% fast-acting insulin aspart), though with marked differences in body weight trajectory (in favour of exenatide) and withdrawal rates (in favour of biphasic insulin aspart) [
1]. However, the study is subject to serious shortcomings. …